We investigated effects of variations in the cellular composition of G-CSF-mobilized peripheral blood progenitor cell (G-PBPC) allografts on clinical outcomes of allogeneic PBPC transplantation. We retrospectively analyzed transplanted doses of various immunocompetent cells from 27 HLA-identical sibling donors in relation to engraftment, incidence of graft-versus-host disease (GVHD), and survival. Significant variability was documented in both absolute numbers and relative proportions of CD34+, CD2+, CD3+, CD4 high +, CD4+25+, CD8 high +, CD19+, CD56+, and CD56+16+ cells contained in these allografts. Stepwise Cox regression analysis revealed that the CD56+ cell dose was significantly inversely correlated with the incidence of GVHD. Thus, there was a significantly higher incidence of grade II acute GVHD in patients receiving a lower CD56+16+ cell dose (hazard ratio (HR) 0.0090; 95% confidence interval (CI), o0.00001-3.38; P ¼ 0.031), a higher incidence of chronic GVHD in those receiving allografts with a lower CD56+16+ to CD34+ ratio (HR o0.00001; 95% CI o0.00001-0.0007; P ¼ 0.0035), and a higher incidence of extensive chronic GVHD in those receiving allografts with a lower CD56+ to CD34+ ratio (HR o0.00001; 95% CI o0.00001-0.053; P ¼ 0.0083). These results suggest that CD56+ cells in G-PBPC allografts from HLA-identical sibling donors may play an important role in preventing the development of GVHD.
Summary:
We investigated effects of variations in the cellular composition of G-CSF-mobilized peripheral blood progenitor cell (G-PBPC) allografts on clinical outcomes of allogeneic PBPC transplantation. We retrospectively analyzed transplanted doses of various immunocompetent cells from 27 HLA-identical sibling donors in relation to engraftment, incidence of graft-versus-host disease (GVHD), and survival. Significant variability was documented in both absolute numbers and relative proportions of CD34+, CD2+, CD3+, CD4 high +, CD4+25+, CD8 high +, CD19+, CD56+, and CD56+16+ cells contained in these allografts. Stepwise Cox regression analysis revealed that the CD56+ cell dose was significantly inversely correlated with the incidence of GVHD. Thus, there was a significantly higher incidence of grade II acute GVHD in patients receiving a lower CD56+16+ cell dose (hazard ratio (HR) 0.0090; 95% confidence interval (CI), o0.00001-3.38; P ¼ 0.031), a higher incidence of chronic GVHD in those receiving allografts with a lower CD56+16+ to CD34+ ratio (HR o0.00001; 95% CI o0.00001-0.0007; P ¼ 0.0035), and a higher incidence of extensive chronic GVHD in those receiving allografts with a lower CD56+ to CD34+ ratio (HR o0.00001; 95% CI o0.00001-0.053; P ¼ 0.0083). These results suggest that CD56+ cells in G-PBPC allografts from HLA-identical sibling donors may play an important role in preventing the development of GVHD. Bone Marrow Transplantation (2003) 32, 505-510. doi:10.1038/sj.bmt.1704165
Keywords: CD56+ cells; G-CSF-mobilized peripheral blood progenitor cells; HLA-identical sibling donors; allogeneic peripheral blood; progenitor cell transplantation; graft-versus-host disease G-CSF-mobilized peripheral blood progenitor cells (G-PBPC) from healthy donors have been used extensively as an alternative to bone marrow cells (BMC) in allogeneic transplantation for treatment of various hematologic malignancies. 1 Several reports indicate that clinical results of stem cell transplantation from HLA-identical sibling donors are improved by substituting G-PBPC for BMC. [2] [3] [4] [5] [6] [7] [8] The biological basis for the improvement of survival observed after allogeneic PBPC transplantation (allo-PBPCT) is not clear, but is likely to be related to differences in the cellular composition of G-PBPC and BMC allografts. [9] [10] [11] In general, engraftment of neutrophils and platelets after allo-PBPCT is faster than after allogeneic bone marrow transplantation (allo-BMT). This difference is considered to be due to the larger dose of CD34+ progenitor cells in G-PBPC allografts compared to BMC. A close relation between the dose of CD34+ cells infused and rapid engraftment has also been shown in the setting of autologous stem cell transplantation.
12 G-PBPC allografts also contain 10-fold more CD3+ cells, 50-fold more CD14+ cells, and 19-fold more CD56+ natural killer (NK) cells than BMC, which may affect engraftment, development of graft-versus-host disease (GVHD), and survival. 5, [13] [14] [15] There have been many reports concerning acute and chronic GVHD in prospective randomized trials comparing allo-PBSCT with allo-BMT, 4, 5, 7, [16] [17] [18] [19] [20] [21] but it is not known whether the incidence of acute and chronic GVHD is associated with differences in the cellular composition between G-PBPC and BMC allografts.
We therefore analyzed the relations between the cellular composition of G-PBPC allografts and clinical outcomes of allo-PBPCT in 27 adult Japanese patients with hematologic malignancies. In this study, the influences of absolute  numbers and relative proportions of CD34+, CD2+,  CD3+, CD4 high +, CD4+CD25+, CD8 high +, CD19+, CD56+, and CD56+16+ cells in G-PBPC allografts on engraftment, acute and chronic GVHD, and survival were investigated.
Materials and methods

Patients
This retrospective analysis included 27 patients who underwent allo-PBPCT from an HLA-identical sibling donor for different hematologic malignancies between March 1996 and May 2001. The results of transplantation were collected from medical records at four participating centers. All results were checked and confirmed by communication with one or more of the investigators at the transplant centers. The median follow-up time was 38.2 months (range 14.4-66.6 months) after transplantation. A total of 16 and 11 patients were categorized into standard-risk and high-risk groups, respectively. The standard-risk group included acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in first complete remission (CR), chronic myeloid leukemia (CML) in first chronic phase (CP) and refractory anemia (RA) of myelodysplastic syndrome (MDS). The high-risk group included AML in second CR, CML in second CP, MDS in RA with excess of blasts (RAEB), RAEB in transformation (RAEB-t), transformation to AML (tAML), and more advanced status of disease.
Donors
Donor selection was based on serological typing for HLA-A, HLA-B, and HLA-DR antigens. G-CSF (filgrastim, Kirin Brewery/Sankyo Co., Tokyo, Japan) was administered subcutaneously to donors at a dose of 400 mg/m 2 per day for 4 or 5 days as previously reported. 22 Leukaphereses were performed using a continuous-flow blood cell separator (Cobe Spectra, Cobe Laboratories, Lakewood, CO, USA) for 1-3 days beginning on day 4 of G-CSF administration until 3.0 Â 10 6 CD34 cells/kg (patient body weight) had been collected. 22 This target dose was achieved in all but one of the donors (4%) by performing two or more leukaphereses. All G-PBPC collected were infused without cryopreservation on either day 0, day 1, or day 2.
Immunophenotyping of G-PBPC
Immunophenotyping of CD34+, CD2+, CD3+, CD4 high +, CD4+CD25+, CD8 high +, CD19+, CD56+, and CD56+16+ cells in each G-PBPC allografts was performed on a FACSCalibur (Becton Dickinson, San Jose, CA, USA) at the Cancer Center, Kyushu University Hospital. For each sample, seven tubes were prepared and processed in parallel according to the following protocols: (1) single staining with CD34 fluorescein isothiocyanate (FITC) (HPCA-2-FITC, Becton Dickinson) and (2) matched isotype controls (Becton Dickinson). Viability of G-PBPC in the tubes prepared according to the protocols was determined by staining with 7-aminoactinomycin-D (7-AAD). Gates were set around forward vs side scatter, and low 7-AAD staining was used to include only viable nucleated cells for further analysis. In addition, two-color FCM was also performed as follows: (1) 
Transplant procedure and supportive care
Patients were conditioned with myeloablative regimens as described in Table 1 . Cyclosporine (CYA) and methotrexate (MTX) were given for standard GVHD prophylaxis. CYA was instituted intravenously from day À1 at a dose of 3 (n ¼ 5) or 5 mg/kg (n ¼ 22) and doses were adjusted to maintain whole blood levels at 200-300 ng/ml. MTX was infused at 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6 (or 7) after transplantation. Grade II acute GVHD was treated with prednisolone according to a standard regimen. 23 In the absence of acute or chronic GVHD, CYA administration was tapered off by 12 months after transplantation, whereas it was continued in patients developing chronic GVHD. 
CD56+ cells associated with GVHD S Yamasaki et al
Engraftment
Engraftment was defined as an absolute neutrophil count (ANC) exceeding 500/ml for three consecutive days after allo-PBPCT. The day of engraftment was determined to be the first of these three consecutive days. Platelet recovery was defined as a platelet count exceeding 20 Â 10 9 /l without platelet support. Graft failure was defined as an ANC never exceeding 0.5 Â 10 9 /l or failing to maintain more than 0.5 Â 10 9 /l for at least three consecutive days by day 28.
Clinical outcomes
The severity of acute GVHD was graded according to the consensus criteria. 24 Chronic GVHD was assessed and graded according to the standard criteria. 25 Progressionfree survival (PFS) was defined as time interval from transplantation to the first event such as relapse, progressive disease, or death. Relapse of the disease was defined as recurrence of the disease including the reappearance of Philadelphia chromosome in CML. Overall survival (OS) was defined as the time between transplantation and death.
Statistical analysis
In order to assess associations of the cellular composition of allografts with the time to neutrophil and platelet engraftment and with the incidence of acute GVHD, we examined variables such as patient and donor age, gender, and disease status. When we analyzed associations of the cellular composition of allografts with the incidence of chronic GVHD, PFS, and OS, we examined variables such as patient and donor age, gender, disease status, and the incidence of acute GVHD. The stepwise Cox regression model for multivariate analysis was used to evaluate these associations. P-values of 0.05 or less were considered to indicate statistical significance. Cumulative incidence estimates were used to show associations of CD56+16+ cell doses with the incidence of grade II acute GVHD, CD56+16+ to CD34+ ratios with chronic GVHD, and CD56+ to CD34+ ratios with extensive chronic GVHD. 26 Statistical analysis was performed with SAS ver 6.07. 
Results
Cellular composition of G-PBPC allografts
Acute and chronic GVHD
The incidence, severity, and onset of acute and chronic GVHD are shown in Table 3 . Grade II acute GVHD developed in six patients (22%); severe acute GVHD (grade III or IV) was not observed. There was a significantly higher incidence of grade II acute GVHD in patients receiving a lower CD56+16+ cell dose (hazard ratio (HR) 0.0090; 95% confidence interval (CI) o0.00001-3.38; P ¼ 0.031) (Table 4, Figure 1 ). There were no significant relations between absolute numbers of CD34+, CD2+, CD3+, CD4 high +, CD4+CD25+, CD8 high +, CD19+, and CD56+ cells or relative proportions of CD34+, CD2+, CD3+, CD4 high +, CD4+CD25+, CD8 high +, CD19+, CD56+, and CD56+16+ cells and the incidence of grade II acute GVHD. Limited and extensive forms of chronic GVHD developed in four (15%) and eight (30%) patients, respectively. The liver was predominantly affected in chronic GVHD, especially in extensive chronic GVHD. An increased incidence of chronic GVHD was observed in patients who received G-PBPC allografts characterized by a lower CD56+16+ to CD34+ ratio (HR o0.00001; 95% CI o0.00001-0.0007; P ¼ 0.0035) (Figure 2 ). In addition, a significantly increased incidence of extensive chronic GVHD was observed in patients who received G-PBPC allografts with a lower CD56+ to CD34+ ratio (HR o0.00001; 95% CI o0.00001-0.053; P ¼ 0.0083) (Figure 3 ). When chronic GVHD was analyzed, no significant associations were found between transplanted doses of CD34+, CD56+, and CD56+16+ cells and chronic GVHD.
Cause of death, relapse, and survival
Five patients died after transplantation; three of them relapsed or progressed, and the remaining two died from extensive chronic GVHD. Probabilities of PFS and OS at 3 years after transplantation were 81.3 and 86.5% in the standard-risk group, and 62.3 and 71.6% in the high-risk group, respectively. There were no significant associations between absolute numbers or relative proportions of CD34+, CD2+, CD3+, CD4 high +, CD4+CD25+, CD8 high +, CD19+, CD56+, or CD56+16+ cells and either PFS or OS.
Discussion
The numbers and proportions of different types of cells contained in G-PBPC allografts were found to vary greatly among donors. Although this variability may be caused by different factors in G-CSF-induced mobilization from healthy donors, differences in numbers of CD34+, CD2+, CD3+, CD4 high +, CD4+25+, CD8 high +, CD19+, CD56+, and Days after transplantation Incidence Figure 3 Extensive chronic GVHD is associated with CD56+ to CD34+ ratios. The incidence of extensive chronic GVHD after allo-PBPCT from HLA-identical siblings is increased in patients receiving allografts with a lower CD56+ to CD34+ ratio: 1 to 4-fold (n ¼ 8, solid line), 5 to 10-fold (n ¼ 9, dashed line), and 11 to 61-fold (n ¼ 10, dotted line).
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CD56+16+ cells in G-PBPC allografts were analyzed in relation to clinical outcomes after allo-PBPCT from an HLA-identical sibling donor. Our findings indicated that a transplanted dose of CD56+ cells was significantly inversely correlated with the incidence of GVHD. There was no significant difference between the time to engraftment and absolute numbers or relative proportions of CD34+, CD2+, CD3+, CD4 high +, CD4+CD25+, CD8 high +, CD19+, CD56+, or CD56+16+ cells in G-PBPC allografts. Zaucha et al 27 demonstrated in a retrospective study that there was a relatively weak association of transplanted dose of CD34+ cells in G-PBPCT allografts from HLA-identical sibling donors with the time to neutrophil engraftment. The reason for the lack of associations found here may be due to the small number of patients analyzed in our study.
It has been demonstrated that T cells such as CD3+ cells, CD4
high + cells, and CD8 high + cells in the graft play a crucial role in the development of acute and chronic GVHD. 28, 29 Clinical results indicate that depletion of T cells with anti-CD3 antibody effectively prevents acute GVHD. 30 However, in the present study, there was no significant association of transplanted doses of CD3+ cells with development of grade II acute GVHD, in agreement with the report of Zaucha et al 27 In the current study, there was a significantly greater incidence of grade II acute GVHD in patients who received G-PBPC allografts containing a lower dose of CD56+16+ cells, especially if this was less than 7.0 Â 10 7 /kg. Ruggeri et al 31 reported that donor NK cells could suppress leukemia relapse and graft rejection as well as protect patients from GVHD. Their results showed that alloreactive NK cells in major-histocompatibility (MHC)-mismatched allo-BMT eradicated human leukemia cells, killed host lymphohematopoietic cells, and reduced GVHD by eliminating recipient-type antigen presenting cells. In a murine allo-BMT model, moreover, cloned T-cell lines expressing NK1.1 (a murine NK cell marker) have been reported to protect against GVHD. 32, 33 Other studies in mice have confirmed that this protection against GVHD is lost after depletion of cells bearing asialo GM1, an NK cell marker. 34 These results suggest that NK cells may play an important role in controlling GVHD and support our findings that double-positive CD56+16+ NK cells might affect grade II acute GVHD, although the number of patients analyzed here was small. A further study to clarify the role of NK cells in allo-PBPCT may be warranted.
In our study, no patients developed grade III and IV acute GVHD. Moreover, five of six patients, who developed grade II acute GVHD, responded well to treatment with prednisolone, suggesting that a combination of CYA and MTX may be optimal for GVHD prophylaxis after allo-PBPCT from HLA-identical sibling donors regardless of the number or type of cells in G-PBPC allografts. In addition to analyzing ethnically different populations, differences in GVHD prophylaxis regimens may explain discrepancies in the incidence of acute GVHD reported in other studies. 27, 35 In the present study, there was a significantly higher incidence of chronic GVHD in patients who received G-PBPC allografts characterized by a lower CD56+16+ to CD34+ ratio, especially when this ratio was seven-fold lower, and also a higher incidence of extensive chronic GVHD in those who received G-PBPC allografts characterized by a lower CD56+ to CD34+ ratio, especially when this ratio was 10-fold lower. However, the association of transplanted doses of CD34+, CD56+, and CD56+16+ cells with chronic GVHD was not statistically significant. NK cells, NKT cells, and precursor cells of T and B cell lineages express surface CD56. This result suggests that patients who received G-PBPC allografts characterized by a lower CD56+16+ to CD34+ ratio and CD56+ to CD34+ ratio may not have received a sufficient dose of double-positive CD56+16+ NK cells or CD34+ cells, together with which dendritic cells might have been transferred, to suppress donor T-cell proliferation. 36 Moreover, to control extensive chronic GVHD, we may also need to transplant a suitable dose of CD56+ cells including CD56+16+ cells as well as CD34+ cells for successful allo-PBPCT. Our result stands in contrast to those reported by Zaucha et al 27 and Przepiorka et al 37 In their study, most of all G-PBPC collected were probably infused with cryopreservation. Moreover, in the study reported by Przepiorka et al, GVHD prophylaxis regimens were different from ours. Therefore, the differences in G-PBPC infused with cryopreservation or those in GVHD prophylaxis regimens may explain the discrepancies between these two studies and ours.
In conclusion, the present study suggests that doublepositive CD56+16+ cells contained in G-PBPC allografts from HLA-identical sibling donors may play an important role in preventing the development of acute GVHD. Moreover, CD56+ cells, especially double-positive CD56+16+ cells, together with an appropriate dose of CD34+ cells, may also influence the development of chronic GVHD. Although further studies of G-PBPC allografts are needed to determine whether cell separation approaches can be applied to allo-PBPCT from HLAidentical sibling donors, our data suggest that technological advances in cell separation of G-PBPC allografts, especially CD56+ cells and CD34+ cells, may influence the development of acute and chronic GVHD after allo-PBPCT.
